Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wai-Kay Seto

Showing results (291-300 of 326) with videos related to

Pageof 33
Sort By:
Alimentary Pharmacology & Therapeutics|October 31, 2023
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksScott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, et al.
Alimentary Pharmacology & Therapeutics|March 6, 2020
Modelling NAFLD disease burden in four Asian regions-2019-2030Chris Estes, Henry L Y Chan, Rong N Chien, et al.
Alimentary Pharmacology & Therapeutics|May 24, 2020
Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action. Authors' replyChris Estes, Henry L Y Chan, Rong N Chien, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
Journal of Gastroenterology and Hepatology|November 22, 2016
Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong KongHenry Lik-Yuen Chan, Owen Tak-Yin Tsang, Yee-Tak Hui, et al.
The American Journal of Gastroenterology|August 10, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone SafetyHenry L Y Chan, Maria Buti, Young-Suk Lim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2020
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J Sonneveld, Jun Yong Park, Apichat Kaewdech, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 23, 2018
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV InfectionWai-Kay Seto, Yasuhiro Asahina, Todd T Brown, et al.
Medcomm|March 3, 2025
Noninvasive Quantification of Hepatic Steatosis Using Ultrasound-Derived Fat Fraction (CHESS2303): A Prospective Multicenter StudyYunlin Huang, Jia Li, Chuan Liu, et al.
Hepatology (Baltimore, Md.)|December 3, 2024
Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgeryRex Wan-Hin Hui, Keith Wan-Hang Chiu, I-Cheng Lee, et al.
Pageof 33

Showing results (291-300 of 326) with videos related to

Sort By:
Pageof 33
Alimentary Pharmacology & Therapeutics|October 31, 2023
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksScott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, et al.
Alimentary Pharmacology & Therapeutics|March 6, 2020
Modelling NAFLD disease burden in four Asian regions-2019-2030Chris Estes, Henry L Y Chan, Rong N Chien, et al.
Alimentary Pharmacology & Therapeutics|May 24, 2020
Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action. Authors' replyChris Estes, Henry L Y Chan, Rong N Chien, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
Journal of Gastroenterology and Hepatology|November 22, 2016
Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong KongHenry Lik-Yuen Chan, Owen Tak-Yin Tsang, Yee-Tak Hui, et al.
The American Journal of Gastroenterology|August 10, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone SafetyHenry L Y Chan, Maria Buti, Young-Suk Lim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2020
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J Sonneveld, Jun Yong Park, Apichat Kaewdech, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 23, 2018
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV InfectionWai-Kay Seto, Yasuhiro Asahina, Todd T Brown, et al.
Medcomm|March 3, 2025
Noninvasive Quantification of Hepatic Steatosis Using Ultrasound-Derived Fat Fraction (CHESS2303): A Prospective Multicenter StudyYunlin Huang, Jia Li, Chuan Liu, et al.
Hepatology (Baltimore, Md.)|December 3, 2024
Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgeryRex Wan-Hin Hui, Keith Wan-Hang Chiu, I-Cheng Lee, et al.
Pageof 33